Treatment target for aggressive leukemia discovered by disrupting its genome organization
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
FierceBiotech1d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
Bone Marrow Donors Can Be Hard to Find. One Company Is Turning to Cadavers
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
Grandmother, 1-year-old granddaughter battle cancer together
When Alicia Fivecoat, a mom of two, felt a golf ball-sized mass under her arm late last year, she said she was devastated to ...
Study reveal single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
Business Insider1d
Sanofi treatment of acute myeloid leukemia granted orphan status
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Healthline13d
Overview of Secondary Acute Myeloid Leukemia
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...
Syndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML Patients
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
A woman with cancer needed stem cells to live. A veteran needed a new mission to survive.
Life was good for Betsy Ehrenberg. It was 2017, and she was 68, a partner at Boston law firm Pyle Rome Ehrenberg PC. She represented unions in collective bargaining matters and workers who’d ...